MICHAEL ITTMANN to Trans-Activators
This is a "connection" page, showing publications MICHAEL ITTMANN has written about Trans-Activators.
Connection Strength
0.413
-
The prostate cancer TMPRSS2:ERG fusion synergizes with the vitamin D receptor (VDR) to induce CYP24A1 expression-limiting VDR signaling. Endocrinology. 2014 Sep; 155(9):3262-73.
Score: 0.081
-
Highly specific targeting of the TMPRSS2/ERG fusion gene using liposomal nanovectors. Clin Cancer Res. 2012 Dec 15; 18(24):6648-57.
Score: 0.073
-
Bortezomib-mediated inhibition of steroid receptor coactivator-3 degradation leads to activated Akt. Clin Cancer Res. 2008 Nov 15; 14(22):7511-8.
Score: 0.055
-
Pleiotropic biological activities of alternatively spliced TMPRSS2/ERG fusion gene transcripts. Cancer Res. 2008 Oct 15; 68(20):8516-24.
Score: 0.055
-
Steroid receptor coactivator-3 and activator protein-1 coordinately regulate the transcription of components of the insulin-like growth factor/AKT signaling pathway. Cancer Res. 2006 Nov 15; 66(22):11039-46.
Score: 0.048
-
SRC-3 is required for prostate cancer cell proliferation and survival. Cancer Res. 2005 Sep 01; 65(17):7976-83.
Score: 0.044
-
Interleukin-6 is an autocrine growth factor in human prostate cancer. Am J Pathol. 2001 Dec; 159(6):2159-65.
Score: 0.034
-
Function of phosphorylation of NF-kB p65 ser536 in prostate cancer oncogenesis. Oncotarget. 2015 Mar 20; 6(8):6281-94.
Score: 0.021